Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 2

Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

,

Panelists discuss how risk stratification tools like IPSS-M are applied in practice for lower-risk myelodysplastic syndromes, addressing prognosis communication and current treatment challenges for this patient group.

Video content above is prompted by the following:

  • Please comment on the risk stratification tools IPSS-M and if you have adapted using this stratification tool in your practice.
  • What do you are share to your patients in terms of prognosis for those with lower-risk MDS?
  • What are some current challenges for treating lower-risk MDS?